Skip to content

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
  • Home
  • About
    • NIH Collaboratory
      • Coordinating Center
      • NIH Collaboratory Trials
      • Core Working Groups
      • Steering Committee
      • Distributed Research Network
      • Our Impact
    • Living Textbook
      • Table of Contents
      • How to Use This Site
  • Resources
    • Data and Resource Sharing
    • Training Resources
    • Tools for Researchers
    • Publications
    • Knowledge Repository
  • Webinar
  • Podcast
  • News
    • News Feed
    • Calendar
    • Subscribe
return to home
Subscribe to Newsletter go to twitter feed go to linkedin go to blue sky feed
Search
NIH Collaboratory
Living Textbook of
Pragmatic Clinical Trials

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
home button

Rethinking Clinical Trials

A Living Textbook of Pragmatic Clinical Trials

  • Design
    • What is a Pragmatic Clinical Trial?
    • Decentralized Pragmatic Clinical Trials
    • Developing a Compelling Grant Application
    • Experimental Designs and Randomization Schemes
    • Endpoints and Outcomes
    • Analysis Plan
    • Using Electronic Health Record Data
    • Building Partnerships and Teams to Ensure a Successful Trial
    • Intervention Delivery and Complexity
    • Patient Engagement
  • Data, Tools & Conduct
    • Assessing Feasibility
    • Acquiring Real-World Data
    • Assessing Fitness-for-Use of Real-World Data
    • Study Startup
    • Participant Recruitment
    • Monitoring Intervention Fidelity and Adaptations
    • Patient-Reported Outcomes
    • Clinical Decision Support
    • Electronic Health Records–Based Phenotyping
    • Navigating the Unknown
  • Interpretation, Dissemination & Implementation
    • Data Sharing and Embedded Research
    • Collaborating With Health System Partners to Review and Understand Trial Results
    • Dissemination Approaches for Different Audiences
    • Implementation
    • End-of-Trial Decision-Making
  • Ethics & Regulatory
    • Privacy Considerations
    • Identifying Those Engaged in Research
    • Collateral Findings
    • Consent, Disclosure, and Non-Disclosure
    • Data and Safety Monitoring
    • Ethical Considerations of Data Sharing in Pragmatic Clinical Trials
    • Ethics for AI and ML
    • IRB Responsibilities and Procedures

Cluster-Crossover Designs

CHAPTER SECTIONS

Experimental Designs and Randomization Schemes


Section 4

Cluster-Crossover Designs

Contributors

Andrea J. Cook, PhD
Fan Li, PhD
David M. Murray, PhD
For the NIH Pragmatic Trials Collaboratory Biostatistics and Study Design Core

Contributing Editor

Damon M. Seils, MA

Cluster randomization is commonly selected for PCTs, because individual-level randomization can raise practical implementation challenges and because outcomes within clusters tend to be correlated. There is an extensive literature on the inefficiency of simple (or “parallel”) cluster randomization compared to individual-level randomization and approaches to accounting for this inefficiency in terms of sample size (Donner et al 1981; Hsieh 1988; Donner 1992; Donner and Klar 1996; Campbell et al 2001).

Modified CRT designs, such as cluster-crossover trials, may reduce the required sample size and may be particularly feasible in PCTs in healthcare systems with EHRs. In this section, we describe cluster-crossover trials and their implications for statistical power and sample size calculations.

Inefficiency and Imbalance in Parallel-Arm CRTs

It is well known that parallel-arm CRTs have less statistical power than individual-level RCTs because of correlation within clusters. Specifically, in a trial designed to determine whether there is a significant difference between interventions A and B on response Y, randomization at the cluster level to either A or B would require a larger sample size to obtain the same statistical power as randomization at the individual level. The magnitude of loss of statistical power is related to the cluster size, the balance of cluster sizes (that is, whether there is variability in cluster sizes), and the correlation of individual-level outcomes within the clusters.

For a given sample size, statistical power increases as the number of clusters increases. This makes intuitive sense, in that as the number of clusters increases, the size of the clusters decreases toward 1, or individual-level randomization. Moreover, as the cluster sizes become more imbalanced, statistical power decreases (Eldridge et al 2009). Also, as correlation within a given cluster increases, power decreases. If there were no intracluster correlation, the power would be the same as with individual-level randomization.

Inefficiency is not the only problem with simple CRT designs. Another challenge is the potential for imbalance in baseline factors, especially with large clusters. For example, in study designs that involve clustering at the clinic level, individual clinics may differ in the size and demographic characteristics of their patient populations. These challenges may be overcome by adding a crossover, or a switch to the other intervention, within cluster during randomization.

Cluster Designs With Crossover

In a cluster-crossover trial, each cluster is randomly assigned to a study condition at the beginning of the study and, after a certain period of time, switches (or crosses over) to the other study condition. Timing the crossover to occur approximately halfway through the study achieves balance between the study conditions, including balance on baseline factors.

A cluster-crossover trial is only feasible if the intervention can be turned off and on without “learning,” such that residual practices are not carried over from the precrossover period to the postcrossover period. A carryover effect would cause contamination between the study conditions. Implementing a washout period after the crossover, during which the data from the clusters are discarded, may help to prevent contamination, though washout periods are not always feasible. For example, in a device trial in which hospitals are randomly assigned to the device intervention or usual care, and in which the outcome of interest is patient survival, a carryover effect may occur despite a washout period due to the time sequence of other potential confounding treatments (for example, a new protocol introduced into the system that improves survival midway through the trial). However, there would likely be a balance of these time effects across the study conditions.

When a cluster-crossover design is feasible, it is statistically more efficient than individual-level randomization in certain situations. Nonetheless, we do not advocate the cluster-crossover approach over individual-level randomization, because of challenges with feasibility (such as turning the intervention on and off) and carryover effects. Rather, a cluster-crossover design can be a viable alternative to simple cluster randomization. The efficiency gained with a cluster-crossover design is like that gained from a paired t test over an independent t test. More power is gained as the between-period correlation within cluster increases (Li et al 2019). Furthermore, when the precrossover and postcrossover periods are balanced with the same number of clusters in each condition, statistical power may increase. As the periods become less balanced, power decreases and the study design becomes more like a simple cluster randomized design.

Cluster Designs With Partial Crossover

If an intervention cannot be turned off and on, another simple alternative is to collect data from all clusters during a baseline period before the intervention is introduced, then assign half of the clusters to the intervention and continue to collect data—in other words, a parallel CRT with a baseline period (Hooper et al 2018; Lee et al 2025). This approach involving an untreated baseline period followed by parallel cluster randomization has statistical advantages because data are available from some clusters to efficiently estimate a within-cluster effect without the potential for “learning” contamination, or carryover effect, that could occur with cluster-crossover designs. Moreover, if outcome data are already being collected through the EHR or medical billing claims, this design is more powerful than a simple CRT design without cost to the study, because the data are already available and easily obtained. A limitation of the design is that not all clusters receive the intervention, unlike other designs such as the stepped-wedge trial. (See the Stepped-Wedge Designs section of this chapter.)

Next Steps

Implementing new cluster-crossover designs would be easier if sample size calculators were available that are simpler than currently available simulation approaches. Li et al (2019) developed sample size calculations for 2-period cluster-crossover designs. There is a need for extensions beyond this standard design.

Previous Section Next Section

SECTIONS

CHAPTER SECTIONS

sections

  1. Introduction
  2. Statistical Design Considerations
  3. Cluster Randomized Trials
  4. Cluster-Crossover Designs
  5. Stepped-Wedge Designs
  6. Choosing Between Cluster and Individual Randomization
  7. Pair Matching and Stratification
  8. Covariate-Constrained Randomization
  9. Concealment and Masking
  10. Designing to Avoid Identification Bias
  11. Additional Resources

Resources

Pragmatic and Group-Randomized Trials in Public Health and Medicine—Part 7. Alternative Designs
Online course From the NIH Office of Disease Prevention

REFERENCES

back to top

Campbell MK, Mollison J, Grimshaw JM. 2001. Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size. Stat Med. 20:391-399. PMID: 11180309.

Donner A. 1992. Sample size requirements for stratified cluster randomization designs. Stat Med. 11:743-750. PMID: 1594813.

Donner A, Birkett N, Buck C. 1981. Randomization by cluster. Sample size requirements and analysis. Am J Epidemiol. 114:906-914. PMID: 7315838.

Donner A, Klar N. 1996. Statistical considerations in the design and analysis of community intervention trials. J Clin Epidemiol. 49:435-439. PMID: 8621994.

Eldridge SM, Ukoumunne OC, Carlin JB. 2009. The intra-cluster correlation coefficient in cluster randomized trials: a review of definitions. Int Stat Rev. 77:378-394. doi:10.1111/j.1751-5823.2009.00092.x.

back to top

Hooper R, Forbes A, Hemming K, Takeda A, Beresford L. 2018. Analysis of cluster randomised trials with an assessment of outcome at baseline. BMJ. 360:k1121. doi: 10.1136/bmj.k1121. PMID: 29559436.

Hsieh FY. 1988. Sample size formulae for intervention studies with the cluster as unit of randomization. Stat Med. 7:1195-1201. PMID: 3201045.

Lee KM, Li F. 2025. How should parallel cluster randomized trials with a baseline period be analyzed? A survey of estimands and common estimators. Biom J. 67(3):e70052. doi: 10.1002/bimj.70052. PMID: 40302411.

Li F, Forbes AB, Turner EL, Preisser JS. Power and sample size requirements for GEE analyses of cluster randomized crossover trials. Stat Med. 2019;38(4):636-649. doi:10.1002/sim.7995. PMID: 30298551.


Version History

July 1, 2026: Made minor text changes as part of the annual content review (changes made by D. Seils).

February 21, 2024: Made minor nonsubstantive text corrections (changes made by D. Seils).

February 7, 2023

current section :

Cluster-Crossover Designs

  1. Introduction
  2. Statistical Design Considerations
  3. Cluster Randomized Trials
  4. Cluster-Crossover Designs
  5. Stepped-Wedge Designs
  6. Choosing Between Cluster and Individual Randomization
  7. Pair Matching and Stratification
  8. Covariate-Constrained Randomization
  9. Concealment and Masking
  10. Designing to Avoid Identification Bias
  11. Additional Resources

Citation:

Cook AJ, Li F, Murray DM; for the NIH Pragmatic Trials Collaboratory Biostatistics and Study Design Core. Experimental Designs and Randomization Schemes: Cluster-Crossover Designs. In: Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials. Bethesda, MD: NIH Pragmatic Trials Collaboratory. Available at: https://rethinkingclinicaltrials.org/chapters/design/experimental-designs-and-randomization-schemes/alternative-cluster-randomized-designs/. Updated July 1, 2026. DOI: 10.28929/205.

Footer Menu

  • How to Use This Site
  • About NIH Collaboratory
  • Enrollment Reporting
  • Grand Rounds
  • Funding Statement
Link to Twitter Link to LinkedIn Link to Blue Sky Link to NIH Collaboratory email

Reference in this Web site to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the U.S. Government or National Institutes of Health (NIH). NIH is not responsible for the contents of any “off-site” Web page referenced from this server.

Log in
Privacy Statement
WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly. Site Map